Candidate Compounds Covid19

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(27 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
{{pnc}}
+
{{gohome}}
 +
{{ft|P}}
 +
  '''CHERRYPICKING STUDIES IS NOT SCIENCE
 +
{{qt|Reviews on covid drug development}}
  
current items will be put into the subsections.
 
  
*[[reviews on covid drug development]]
+
*'''[[scouting ideas]]'''
*[[scouting ideas]]
+
  
*[[Patients on biologicals]]
+
*'''[[PHA Biologicals]]'''
*[[HMGB1, RAGE]]
+
*[[pre-Interleukin 6]]
+
*[[post-Interleukin 6]]
+
*[[pre-TNFalpha]]
+
*[[post-TNFalpha]]
+
*[[pre-Interleukin 17]]
+
*[[post-Interleukin 17]]
+
*[[pre-Interleukin 1]]
+
*[[post-Interleukin 1]]
+
*[[Inflammasome]] ''colchicine''
+
*[[Methotrexate]]
+
*[[other anti-inflammatory]]
+
*[[NK-kappaB]]
+
*[[STAT 3]]
+
*[[JAK Janus Kinase]]
+
*[[Corticosteroids]]
+
*[[Cytokine absorbers]]
+
*[[Target Complement system]]
+
*[[Target Extracellular traps]]
+
*[[TGF beta]]
+
*[[Anticoagulant in covid19]]
+
*[[Antioxidants]]
+
*[[Stem cells]]
+
*[[MDSC cells]]
+
*[[Interferons]]
+
  
 +
*'''[[PHA conventional pharmacology]]'''
  
*[[other single compounds]]
+
*'''[[PHA retargeted compounds]]'''
*[[Retargeted single compounds]]
+
*[[Hydroxychloroquine]]
+
*
+
*[[Target ACE2, Spike protein]]
+
*[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
+
*[[other antiviral compounds]]
+
*[[AV Remdesivir]]
+
*[[AV Lopinavir]]
+
*[[AV Ivermectin]]
+
*[[AV Arabidol]]
+
*[[AV Favipiravir]]
+
  
 +
*'''[[PHA antivirals by mechanism]]'''
  
 +
*'''[[PHA pharmacophore by screened target]]'''
  
*[[Vitamin D]]
+
*'''[[PHA ImmunoNutrients]]
*[[Anorganic nutrients Magnesium]]
+
*[[Anorganic nutrients Selenium]]
+
*[[Anorganic nutrients Zinc]]
+
*[[Nutrition, general]]
+
*[[Exercise, Vibration]]
+
  
 +
*'''[[PHA compl altern natural]]'''
  
*[[Traditional Chinese Medicine]]
+
*'''[[PHA within indications compounds]]'''
*[[Natural compounds]]
+
  
*[[Statins]]
+
*'''[[PHA Serum products]]'''
*[[Antidiabetic compounds, any]]
+
*[[RSP - On RAS drugs]]
+
  
*[[Reconvalescent blood products, Passive vaccine]]  
+
*'''[[PHA Vaccination]]'''
*[[Plasmapheresis]]
+
 
 +
PHA related options:
  
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
 
 
*[[Radiation therapy]]
 
*[[Radiation therapy]]
 
*[[Phototherapy]]
 
*[[Phototherapy]]
*[[Active vaccine]]  
+
*[[Electric fields]]
 
+
 
*[[Treatment other concepts]]
 
*[[Treatment other concepts]]
  
===-rest-===
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
===009===
 
 
 
{{tp|p=32535032|t=2020. Vitamin D Receptor stimulation to reduce Acute Respiratory Distress Syndrome (ARDS) in patients with Coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.|pdf=|usr=009}}
 
 
{{tp|p=32423449|t=2020. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.|pdf=|usr=009}}
 
 
{{tp|p=32405423|t=2020. Minimum costs to manufacture new treatments for COVID-19.|pdf=|usr=009}}
 
{{tp|p=32405422|t=2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.|pdf=|usr=009}}
 
{{tp|p=32405421|t=2020. A review of the safety of favipiravir - a potential treatment in the COVID-19 pandemic?|pdf=|usr=009}}
 
{{tp|p=32401274|t=2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.|pdf=|usr=009}}
 
 
{{tp|p=32501511|t=2020. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.|pdf=|usr=009}}
 
{{tp|p=32530438|t=2020. New (re)Purpose for an old drug: purinergic receptor blockade may extinguish the COVID-19 thrombo-inflammatory firestorm.|pdf=|usr=009}}
 
{{tp|p=32459647|t=2020. Intra-Rater and Inter-Rater Reliability of Tongue Coating Diagnosis in Traditional Chinese Medicine Using Smartphones: Quasi-Delphi Study.|pdf=|usr=009}}
 
{{tp|p=32384188|t=2020. Parenteral Fish-Oil Emulsions in Critically Ill COVID-19 Emulsions.|pdf=|usr=009}}
 
{{tp|p=32401715|t=2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.|pdf=|usr=009}}
 
{{tp|p=32401712|t=2020. Interferon beta-1b for COVID-19.|pdf=|usr=009}}
 
{{tp|p=32410758|t=2020. Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.|pdf=|usr=009}}
 
 
{{tp|p=32464115|t=2020. Caution against corticosteroid-based COVID-19 treatment.|pdf=|usr=009}}
 
{{tp|p=32445630|t=2020. Vitamin-D and COVID-19: do deficient risk a poorer outcome?|pdf=|usr=009}}
 
{{tp|p=32501454|t=2020. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.|pdf=|usr=009}}
 
{{tp|p=32518419|t=2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.|pdf=|usr=009}}
 
{{tp|p=32528040|t=2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.|pdf=|usr=009}}
 
 
{{tp|p=32535080|t=2020. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.|pdf=|usr=009}}
 
{{tp|p=32497632|t=2020. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.|pdf=|usr=009}}
 
{{tp|p=32454157|t=2020. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.|pdf=|usr=009}}
 
{{tp|p=32450171|t=2020. Coronaviruses pandemics: Can neutralizing antibodies help?|pdf=|usr=009}}
 
{{tp|p=32450166|t=2020. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.|pdf=|usr=009}}
 
{{tp|p=32422305|t=2020. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.|pdf=|usr=009}}
 
 
{{tp|p=32478465|t=2020. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.|pdf=|usr=009}}
 
{{tp|p=32532461|t=2020. Eficacia de los pulsos de corticoides en pacientes con sindrome de liberacion de citocinas inducido por infeccion por SARS-CoV-2.|pdf=|usr=009}}
 
 
{{tp|p=32416415|t=2020. Etoposide-based therapy for severe forms of COVID-19.|pdf=|usr=009}}
 
{{tp|p=32516655|t=2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.|pdf=|usr=009}}
 
{{tp|p=32504923|t=2020. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.|pdf=|usr=009}}
 
{{tp|p=32485316|t=2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.|pdf=|usr=009}}
 
{{tp|p=32498007|t=2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.|pdf=|usr=009}}
 
{{tp|p=32492562|t=2020. The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast.|pdf=|usr=009}}
 
{{tp|p=32480250|t=2020. Protective effects of vaccinations and endemic infections on COVID-19: A hypothesis.|pdf=|usr=009}}
 
{{tp|p=32464491|t=2020. Selenium supplementation in the prevention of coronavirus infections (COVID-19).|pdf=|usr=009}}
 
{{tp|p=32526511|t=2020. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2.|pdf=|usr=009}}
 
{{tp|p=32473509|t=2020. Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of SARS-CoV-2 and other viral infections.|pdf=|usr=009}}
 
{{tp|p=32470789|t=2020. Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.|pdf=|usr=009}}
 
{{tp|p=32534175|t=2020. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.|pdf=|usr=009}}
 
{{tp|p=32464494|t=2020. Homocysteine as a potential predictor of cardiovascular risk in patients with COVID-19.|pdf=|usr=009}}
 
{{tp|p=32526507|t=2020. Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.|pdf=|usr=009}}
 
{{tp|p=32464493|t=2020. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis.|pdf=|usr=009}}
 
{{tp|p=32464492|t=2020. Can moderate intensity aerobic exercise be an effective and valuable therapy in preventing and controlling the pandemic of COVID-19?|pdf=|usr=009}}
 
{{tp|p=32460208|t=2020. Sodium chromo-glycate and palmitoylethanolamide: A possible strategy to treat mast cell-induced lung inflammation in COVID-19.|pdf=|usr=009}}
 
{{tp|p=32425307|t=2020. Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.|pdf=|usr=009}}
 
{{tp|p=32425306|t=2020. Protective potential of Expectorants against COVID-19.|pdf=|usr=009}}
 
{{tp|p=32416408|t=2020. As a potential treatment of COVID-19: Montelukast.|pdf=|usr=009}}
 
{{tp|p=32413699|t=2020. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.|pdf=|usr=009}}
 
{{tp|p=32531538|t=2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?|pdf=|usr=009}}
 
{{tp|p=32531537|t=2020. RAGE receptor: May be a potential inflammatory mediator for SARS-COV-2 infection?|pdf=|usr=009}}
 
{{tp|p=32516733|t=2020. B-cell engineering: A promising approach towards vaccine development for COVID-19.|pdf=|usr=009}}
 
{{tp|p=32535456|t=2020. Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana.|pdf=|usr=009}}
 
{{tp|p=32534337|t=2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.|pdf=|usr=009}}
 
{{tp|p=32505075|t=2020. Fighting against frailty and sarcopenia - As well as COVID-19?|pdf=|usr=009}}
 
{{tp|p=32505072|t=2020. COVID-19 and picotechnology: Potential opportunities.|pdf=|usr=009}}
 
{{tp|p=32505069|t=2020. Hydrogen peroxide and viral infections: A literature review with research hypothesis definition in relation to the current covid-19 pandemic.|pdf=|usr=009}}
 
{{tp|p=32400020|t=2020. COVID-19 and implications for thiopurine use.|pdf=|usr=009}}
 
{{tp|p=32395220|t=2020. SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.|pdf=|usr=009}}
 
{{tp|p=32470350|t=2020. Commentary: Myths and facts on vitamin D amidst the COVID-19 pandemic.|pdf=|usr=009}}
 
{{tp|p=32497535|t=2020. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.|pdf=|usr=009}}
 
{{tp|p=32418885|t=2020. Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?|pdf=|usr=009}}
 
{{tp|p=32473390|t=2020. A review of South Indian medicinal plant has the ability to combat against deadly viruses along with COVID-19?|pdf=|usr=009}}
 
 
{{tp|p=32445881|t=2020. Arbidol/IFN-alpha2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.|pdf=|usr=009}}
 
{{tp|p=32442649|t=2020. Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives.|pdf=|usr=009}}
 
 
{{tp|p=32404512|t=2020. Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?|pdf=|usr=009}}
 
 
{{tp|p=32445439|t=2020. Surgery Scheduling in a Crisis.|pdf=|usr=009}}
 
 
{{tp|p=32529545|t=2020. Natural Products as Potential Leads Against Coronaviruses: Could They be Encouraging Structural Models Against SARS-CoV-2?|pdf=|usr=009}}
 
 
{{tp|p=32533109|t=2020. Passive antibody therapy in COVID-19.|pdf=|usr=009}}
 
{{tp|p=32393823|t=2020. BCG-induced trained immunity: can it offer protection against COVID-19?|pdf=|usr=009}}
 
{{tp|p=32462282|t=2020. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.|pdf=|usr=009}}
 
{{tp|p=32451597|t=2020. Vitamin D can prevent COVID-19 infection-induced multiple organ damage.|pdf=|usr=009}}
 
{{tp|p=32430617|t=2020. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19).|pdf=|usr=009}}
 
 
{{tp|p=32342609|t=2020. The Use of Non-invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID-19: A Theoretical Hypothesis and Early Clinical Experience.|pdf=|usr=009}}
 
{{tp|p=32383751|t=2020. Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19.|pdf=|usr=009
 
{{tp|p=32521760|t=2020. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review.|pdf=|usr=009}}
 
{{tp|p=32532069|t=2020. Can Probiotics and Diet Promote Beneficial Immune Modulation and Purine Control in Coronavirus Infection?|pdf=|usr=009}}
 
{{tp|p=32519174|t=2020. What can we learn about corticosteroid therapy as a treatment for COVID-19?|pdf=|usr=009}}
 
{{tp|p=32528623|t=2020. COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment?|pdf=|usr=009}}
 
 
{{tp|p=32431755|t=2020. The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the "cytokine storm" in COVID-19 patients: a hypothesis.|pdf=|usr=009}}
 
{{tp|p=32451736|t=2020. Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19.|pdf=|usr=009}}
 
{{tp|p=32454586|t=2020. Demand for potentially hazardous COVID-19 treatments.|pdf=|usr=009}}
 
{{tp|p=32454583|t=2020. ICER releases pricing models for potential COVID-19 treatments.|pdf=|usr=009}}
 
{{tp|p=32473310|t=2020. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.|pdf=|usr=009}}
 
 
{{tp|p=32445955|t=2020. Letter to the Editor in response to the article "Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?"|pdf=|usr=009}}
 
 
{{tp|p=32430287|t=2020. Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartter's and Gitelman's syndrome patients.|pdf=|usr=009}}
 
 
 
{{tp|p=32405226|t=2020. Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.|pdf=|usr=009}}
 
 
 
 
{{tp|p=32502640|t=2020. Optimising effectiveness of health care and value of clinical trials in the COVID -19 outbreak.|pdf=|usr=009}}
 
{{tp|p=32470470|t=2020. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.|pdf=|usr=009}}
 
{{tp|p=32442437|t=2020. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.|pdf=|usr=009}}
 
{{tp|p=32437972|t=2020. COVID-19: Beyond the virus. The use of Photodynamic Therapy for the Treatment of Infections in the Respiratory Tract.|pdf=|usr=009}}
 
 
{{tp|p=32493609|t=2020. SGLT-2 inhibitors for COVID-19 - A miracle waiting to happen or just another beat around the bush?|pdf=|usr=009}}
 
{{tp|p=32519302|t=2020. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.|pdf=|usr=009}}
 
{{tp|p=32415971|t=2020. Use of statins in patients with COVID-19.|pdf=|usr=009}}
 
{{tp|p=32415962|t=2020. Reply: Use of statins in patients with COVID-19.|pdf=|usr=009}}
 
{{tp|p=32522574|t=2020. Coping with hypoxemia: Could erythropoietin (EPO) be an adjuvant treatment of COVID-19?|pdf=|usr=009}}
 
{{tp|p=32514354|t=2020. High-dose, short-term corticosteroids for ARDS caused by COVID-19: a case series.|pdf=|usr=009}}
 
 
{{tp|p=32426002|t=2020. Opciones Terapeuticas En El Manejo De Covid-19 Grave: Una Perspectiva De Reumatologia.|pdf=|usr=009}}
 
{{tp|p=32426001|t=2020. Colchicina: una herramienta terapeutica potencial frente a COVID-19. Experiencia en 5 pacientes.|pdf=|usr=009}}
 
 
{{tp|p=32414660|t=2020. Exercising in times of COVID-19: what do experts recommend doing within four walls?|pdf=|usr=009}}
 
{{tp|p=32491104|t=2020. Clinical characteristics and therapeutic procedure for a critical case of novel coronavirus pneumonia treated with glucocorticoids and non-invasive ventilator treatment.|pdf=|usr=009}}
 
 
 
{{tp|p=32404477|t=2020. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.|pdf=|usr=009}}
 
 
{{tp|p=32467561|t=2020. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.|pdf=|usr=009}}
 
{{tp|p=32460839|t=2020. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.|pdf=|usr=009}}
 
{{tp|p=32526079|t=2020. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.|pdf=|usr=009}}
 
{{tp|p=32412544|t=2020. In silico fight against novel coronavirus by finding chromone derivatives as inhibitor of coronavirus main proteases enzyme.|pdf=|usr=009}}
 
 
 
{{tp|p=32436460|t=2020. TNFalpha inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.|pdf=|usr=009}}
 
{{tp|p=32436445|t=2020. Potential specific therapies in COVID-19.|pdf=|usr=009}}
 
{{tp|p=32483428|t=2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients.|pdf=|usr=009}}
 
{{tp|p=32487513|t=2020. Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis.|pdf=|usr=009}}
 
{{tp|p=32532691|t=2020. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.|pdf=|usr=009}}
 
{{tp|p=32467007|t=2020. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.|pdf=|usr=009}}
 
{{tp|p=32425645|t=2020. Use of convalescent plasma in COVID-19 patients in China.|pdf=|usr=009}}
 
{{tp|p=32406985|t=2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient.|pdf=|usr=009}}
 
 
{{tp|p=32471655|t=2020. Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-Analyses.|pdf=|usr=009}}
 
{{tp|p=32454984|t=2020. Battling COVID-19: using old weapons for a new enemy.|pdf=|usr=009}}
 
{{tp|p=32376108|t=2020. Archetype analysis of older adult immunization decision-making and implementation in 34 countries.|pdf=|usr=009}}
 
{{tp|p=32236815|t=2020. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.|pdf=|usr=009}}
 
 
{{tp|p=32530808|t=2020. Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series.|pdf=|usr=009}}
 
{{tp|p=32531236|t=2020. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.|pdf=|usr=009}}
 
{{tp|p=32532094|t=2020. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.|pdf=|usr=009}}
 
{{tp|p=32532085|t=2020. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).|pdf=|usr=009}}
 
{{tp|p=32426090|t=2020. COVID-19, asthma, and biologic therapies: What we need to know.|pdf=|usr=009}}
 
{{tp|p=32417996|t=2020. BCG versus COVID-19: impact on urology.|pdf=|usr=009}}
 
{{tp|p=32514854|t=2020. Biologikatherapie nach COVID-19-Infektion : Keine Reaktivierung einer COVID-19-Infektion bei positivem Antikorperstatus SARS-CoV-2 unter Biologikatherapie.|pdf=|usr=009}}
 
 
 
 
 
 
 
{{tp|p=32555446|t=2020. Overview of therapeutic drug research for COVID-19 in China.|pdf=|usr=010}}
 
 
{{tp|p=32574894|t=2020. Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.|pdf=|usr=010}}
 
{{tp|p=32583087|t=2020. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.|pdf=|usr=010}}
 
 
{{tp|p=32543882|t=2020. Promoting Better Clinical Trials and Drug Information as Public Health Interventions for the COVID-19 Emergency in Italy.|pdf=|usr=010}}
 
{{tp|p=32571831|t=2020. IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY.|pdf=|usr=010}}
 
{{tp|p=32575554|t=2020. Targeting the Heme-Heme Oxygenase System to Prevent Severe Complications Following COVID-19 Infections.|pdf=|usr=010}}
 
{{tp|p=32562705|t=2020. A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.|pdf=|usr=010}}
 
{{tp|p=32557214|t=2020. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.|pdf=|usr=010}}
 
{{tp|p=32586336|t=2020. A prospect on the use of antiviral drugs to control local outbreaks of COVID-19.|pdf=|usr=010}}
 
 
{{tp|p=32572174|t=2020. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.|pdf=|usr=010}}
 
{{tp|p=32546835|t=2020. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?|pdf=|usr=010}}
 
 
{{tp|p=32492407|t=2020. Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19.|pdf=|usr=010}}
 
{{tp|p=32546764|t=2020. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.|pdf=|usr=010}}
 
{{tp|p=32541865|t=2020. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.|pdf=|usr=010}}
 
{{tp|p=32588163|t=2020. Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.|pdf=|usr=010}}
 
{{tp|p=32585295|t=2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.|pdf=|usr=010}}
 
{{tp|p=32564213|t=2020. The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.|pdf=|usr=010}}
 
{{tp|p=32564212|t=2020. Comment on "Colchicine may not be effective in COVID-19 infection; it may even be harmful?"|pdf=|usr=010}}
 
{{tp|p=32556936|t=2020. Colchicine as a possible therapeutic option in COVID-19 infection.|pdf=|usr=010}}
 
{{tp|p=32548723|t=2020. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19.|pdf=|usr=010}}
 
 
{{tp|p=32593060|t=2020. Helping doctors hasten COVID-19 treatment: Towards a rescue framework for the transfusion of best convalescent plasma to the most critical patients based on biological requirements via ml and novel MCDM methods.|pdf=|usr=010}}
 
{{tp|p=32558354|t=2020. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load.|pdf=|usr=010}}
 
{{tp|p=32552848|t=2020. Compassionate use of others' immunity - understanding gut microbiome in Covid-19.|pdf=|usr=010}}
 
{{tp|p=32552832|t=2020. First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19.|pdf=|usr=010}}
 
{{tp|p=32572376|t=2020. Literature-based review of the drugs used for the treatment of COVID-19.|pdf=|usr=010}}
 
{{tp|p=32578027|t=2020. A Rapid Advice Guideline for the Prevention of Novel Coronavirus Through Nutritional Intervention.|pdf=|usr=010}}
 
{{tp|p=32562159|t=2020. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.|pdf=|usr=010}}
 
{{tp|p=32542964|t=2020. Treatment of Covid19 - Repurposing drugs commonly used in dermatology.|pdf=|usr=010}}
 
 
{{tp|p=32537890|t=2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.|pdf=|usr=010}}
 
{{tp|p=32592841|t=2020. A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19.|pdf=|usr=010}}
 
{{tp|p=32581194|t=2020. Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?|pdf=|usr=010}}
 
{{tp|p=32554953|t=2020. Can mesenchymal stem cell therapy be the interim management of COVID-19?|pdf=|usr=010}}
 
 
{{tp|p=32574699|t=2020. Discovering small-molecule therapeutics against SARS-CoV-2.|pdf=|usr=010}}
 
{{tp|p=32574697|t=2020. Current and future therapeutical approaches for COVID-19.|pdf=|usr=010}}
 
{{tp|p=32569833|t=2020. Exportin 1 inhibition as antiviral therapy.|pdf=|usr=010}}
 
{{tp|p=32546018|t=2020. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.|pdf=|usr=010}}
 
 
{{tp|p=32592145|t=2020. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells.|pdf=|usr=010}}
 
{{tp|p=32574958|t=2020. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.|pdf=|usr=010}}
 
{{tp|p=32573433|t=2020. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization.|pdf=|usr=010}}
 
{{tp|p=32569446|t=2020. Can artificial intelligence identify effective COVID-19 therapies?|pdf=|usr=010}}
 
{{tp|p=32579067|t=2020. In Vivo Expressed Biologics for Infectious Disease Prophylaxis: Rapid Delivery of DNA-Based Antiviral Antibodies.|pdf=|usr=010}}
 
{{tp|p=32562594|t=2020. Pregnant Women in Trials of COVID-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.|pdf=|usr=010}}
 
{{tp|p=32561291|t=2020. Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?|pdf=|usr=010}}
 
{{tp|p=32554535|t=2020. Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors (nAChR) and beyond.|pdf=|usr=010}}
 
{{tp|p=32589055|t=2020. Vesicular drug-delivery systems as theranostics in COVID-19.|pdf=|usr=010}}
 
{{tp|p=32564623|t=2020. Tackling SARS-CoV-2: proposed targets and repurposed drugs.|pdf=|usr=010}}
 
{{tp|p=32578073|t=2020. Elderly at time of COronaVIrus disease 2019 (COVID-19): possible role of immunosenescence and malnutrition.|pdf=|usr=010}}
 
{{tp|p=32577840|t=2020. Introduction: microbes, networks, knowledge-disease ecology and emerging infectious diseases in time of COVID-19.|pdf=|usr=010}}
 
{{tp|p=32544304|t=2020. Antiretroviral HIV drugs in COVID-19 research: promises and risks. An opinion piece.|pdf=|usr=010}}
 
{{tp|p=32591003|t=2020. Application of CRISPR/Cas9 to human-induced pluripotent stem cells: from gene editing to drug discovery.|pdf=|usr=010}}
 
{{tp|p=32546029|t=2020. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019.|pdf=|usr=010}}
 
 
{{tp|p=32588335|t=2020. COVID-19, equipoise and observational studies: a reminder of forgotten issues.|pdf=|usr=010}}
 
{{tp|p=32557206|t=2020. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.|pdf=|usr=010}}
 
{{tp|p=32582401|t=2020. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.|pdf=|usr=010}}
 
{{tp|p=32582400|t=2020. Steps towards COVID-19 suppression.|pdf=|usr=010}}
 
 
 
{{tp|p=32585284|t=2020. Therapeutic Plasma Exchange in Adults with Severe COVID-19 Infection.|pdf=|usr=010}}
 
{{tp|p=32579907|t=2020. Paromomycin: a potential dual targeted drug effectively inhibits both Spike (S1) and Main Protease of COVID-19.|pdf=|usr=010}}
 
{{tp|p=32585194|t=2020. Convalescent plasma therapy in the treatment of COVID-19: Some considerations: Correspondence.|pdf=|usr=010}}
 
{{tp|p=32592113|t=2020. Potential role of incretins in diabetes and COVID-19 infection: a hypothesis worth exploring.|pdf=|usr=010}}
 
 
 
{{tp|p=32588377|t=2020. Corticosteroids in diabetes patients infected with COVID-19.|pdf=|usr=010}}
 
 
{{tp|p=32578215|t=2020. Could Anti-Tubercular Vaccination Protect Against Covid-19 Infection?|pdf=|usr=010}}
 
{{tp|p=32552021|t=2020. From "Infodemics" to Health Promotion: A Novel Framework for the Role of Social Media in Public Health.|pdf=|usr=010}}
 
{{tp|p=32579022|t=2020. Lung Mechanics in COVID-19 Resemble RDS not ARDS: Could Surfactant be a Treatment?|pdf=|usr=010}}
 
{{tp|p=32579020|t=2020. Treatment of COVID-19 by Inhaled NO to Reduce Shunt?|pdf=|usr=010}}
 
{{tp|p=32551560|t=2020. Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.|pdf=|usr=010}}
 
{{tp|p=32585180|t=2020. Use of inhaled corticosteroids in asthma and COVID-19 : Keep calm and carry on.|pdf=|usr=010}}
 
 
{{tp|p=32561608|t=2020. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients.|pdf=|usr=010}}
 
{{tp|p=32574109|t=2020. Structural Basis of the SARS-CoV-2/SARS-CoV Receptor Binding and Small-Molecule Blockers as Potential Therapeutics.|pdf=|usr=010}}
 
 
{{tp|p=32551883|t=2020. COVID-19 and the Drug Repurposing Tsunami.|pdf=|usr=010}}
 
{{tp|p=32573724|t=2020. Improved Clinical Symptoms and Mortality on Severe/Critical COVID-19 Patients Utilizing Convalescent Plasma Transfusion.|pdf=|usr=010}}
 
{{tp|p=32559767|t=2020. Use of Convalescent Plasma in Hospitalized Patients with Covid-19 - Case Series.|pdf=|usr=010}}
 
{{tp|p=32576548|t=2020. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes preprint.|pdf=|usr=010}}
 
{{tp|p=32546467|t=2020. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds.|pdf=|usr=010}}
 
 
 
{{tp|p=32548616|t=2020. Corticosteroids in patients with COVID-19: what about the control group?|pdf=|usr=010}}
 
 
 
 
{{tp|p=32584431|t=2020. Colchicin Treatment of Covid-19 Presenting With Cutaneous Rash and Myopericarditis.|pdf=|usr=010}}
 
{{tp|p=32562762|t=2020. SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?|pdf=|usr=010}}
 
 
{{tp|p=32588937|t=2020. Adjustments in analyses of vitamin D status, allowing for vitamin D determinants, for Covid-19 risks.|pdf=|usr=010}}
 
{{tp|p=32559771|t=2020. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.|pdf=|usr=010}}
 
{{tp|p=32588530|t=2020. RNA to the rescue: RNA is one of the most promising targets for drug development given its wide variety of uses.|pdf=|usr=010}}
 
{{tp|p=32567239|t=2020. Advantages of Using Lotteries to Select Participants for High-Demand Covid-19 Treatment Trials.|pdf=|usr=010}}
 
 
{{tp|p=32574081|t=2020. Can nanotechnology help in the fight against COVID-19?|pdf=|usr=010}}
 
{{tp|p=32552044|t=2020. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges.|pdf=|usr=010}}
 
{{tp|p=32576053|t=2020. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients.|pdf=|usr=010}}
 
{{tp|p=32553760|t=2020. TNFalpha-antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease TMPRSS2 in patients with inflammatory bowel disease.|pdf=|usr=010}}
 
{{tp|p=32553757|t=2020. Aminosalicylates and COVID-19: Facts or Coincidences?|pdf=|usr=010}}
 
{{tp|p=32554621|t=2020. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.|pdf=|usr=010}}
 
 
 
{{tp|p=32557541|t=2020. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.|pdf=|usr=010}}
 
{{tp|p=32561274|t=2020. In silico prediction of potential inhibitors for the Main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.|pdf=|usr=010}}
 
 
 
{{tp|p=32539378|t=2020. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.|pdf=|usr=010}}
 
{{tp|p=32562701|t=2020. Apelin-potential therapy for COVID-19?|pdf=|usr=010}}
 
 
 
{{tp|p=32543196|t=2020. Repositioning of 8565 Existing Drugs for COVID-19.|pdf=|usr=010}}
 
{{tp|p=32586380|t=2020. Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19).|pdf=|usr=010}}
 
 
{{tp|p=32589146|t=2020. Statistical Issues and Lessons Learned from COVID-19 Clinical Trials with Lopinavir-Ritonavir and Remdesivir.|pdf=|usr=010}}
 
 
{{tp|p=32553190|t=2020. Appropriate selection of convalescent plasma donors for COVID-19.|pdf=|usr=010}}
 
{{tp|p=32555367|t=2020. Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.|pdf=|usr=010}}
 
{{tp|p=32555296|t=2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).|pdf=|usr=010}}
 
 
{{tp|p=32561657|t=2020. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?|pdf=|usr=010}}
 
{{tp|p=32590324|t=2020. Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis.|pdf=|usr=010}}
 
{{tp|p=32575019|t=2020. Pirfenidone: A novel hypothetical treatment for COVID-19.|pdf=|usr=010}}
 
{{tp|p=32558640|t=2020. Cibler la protease majeure du SARS-CoV-2 pour fabriquer un medicament efficace contre ce coronavirus.|pdf=|usr=010}}
 
{{tp|p=32590819|t=2020. Critically ill patients with COVID-19 with ECMO and artificial liver plasma exchange: A retrospective study.|pdf=|usr=010}}
 
{{tp|p=32574789|t=2020. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19).|pdf=|usr=010}}
 
{{tp|p=32570850|t=2020. Microbiota Modulating Nutritional Approaches to Countering the Effects of Viral Respiratory Infections Including SARS-CoV-2 through Promoting Metabolic and Immune Fitness with Probiotics and Plant Bioactives.|pdf=|usr=010}}
 
{{tp|p=32546125|t=2020. Erythropoietin as candidate for supportive treatment of severe COVID-19.|pdf=|usr=010}}
 
{{tp|p=32560203|t=2020. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review.|pdf=|usr=010}}
 
{{ttp|p=32551679|t=2020. Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity.|pdf=|usr=010}}
 
{{tp|p=32557405|t=2020. Recognition of Natural Products as Potential Inhibitors of COVID-19 Main Protease (Mpro): In-Silico Evidences.|pdf=|usr=010}}
 
{{tp|p=32576980|t=2020. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches.|pdf=|usr=010}}
 
 
 
{{tp|p=32587103|t=2020. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?|pdf=|usr=010}}
 
{{tp|p=32590117|t=2020. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19.|pdf=|usr=010}}
 
{{tp|p=32405159|t=2020. May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?|pdf=|usr=010}}
 
{{tp|p=32564413|t=2020. Is 0.5% Hydrogen Peroxide Effective against SARS-CoV-2?|pdf=|usr=010}}
 
{{tp|p=32587806|t=2020. A potential role for Galectin-3 inhibitors in the treatment of COVID-19.|pdf=|usr=010}}
 
 
 
{{tp|p=32565309|t=2020. Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019.|pdf=|usr=010}}
 
{{tp|p=32592716|t=2020. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?|pdf=|usr=010}}
 
{{tp|p=32562826|t=2020. Therapeutic potential of resveratrol against emerging respiratory viral infections.|pdf=|usr=010}}
 
{{tp|p=32542785|t=2020. Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID-19.|pdf=|usr=010}}
 
{{tp|p=32592911|t=2020. Does photodynamic therapy have potential in the treatment of COVID 19 patients?|pdf=|usr=010}}
 
{{tp|p=32585401|t=2020. Optical theranostics and treatment dosimetry for COVID-19 lung complications: towards increasing the survival rate of vulnerable populations.|pdf=|usr=010}}
 
{{tp|p=32585400|t=2020. Ultraviolet-based biophotonic technologies for control and prevention of COVID-19, SARS and related disorders.|pdf=|usr=010}}
 
 
 
 
{{tp|p=32570995|t=2020. Short-Term Dexamethasone in Sars-CoV-2 Patients.|pdf=|usr=010}}
 
{{tp|p=32552811|t=2020. E-cigarette-induced pulmonary inflammation and dysregulated repair are mediated by nAChR alpha7 receptor: role of nAChR alpha7 in SARS-CoV-2 Covid-19 ACE2 receptor regulation.|pdf=|usr=010}}
 
{{tp|p=32558034|t=2020. National policies for paediatric universal BCG vaccination were associated with decreased mortality due to COVID-19.|pdf=|usr=010}}
 
{{tp|p=32557955|t=2020. Targeting the interleukin-17 pathway to prevent acute respiratory distress syndrome associated with SARS-CoV-2 infection.|pdf=|usr=010}}
 
{{tp|p=32571730|t=2020. Anakinra, una alternativa potencial en el tratamiento de la infeccion respiratoria grave por SARS-CoV-2 refractaria a tocilizumab.|pdf=|usr=010}}
 
{{ttp|p=32579014|t=2020. Systemic inflammatory response and thrombosis due to alterations in the gut microbiota in COVID-19.|pdf=|usr=010}}
 
{{ttp|p=32579012|t=2020. COVID-19. Immunothrombosis and the gastrointestinal tract.|pdf=|usr=010}}
 
 
{{tp|p=32568026|t=2020. Targeting infectious Coronavirus Disease 2019 (COVID-19) with Artificial Intelligence (AI) applications: Evidence based opinion.|pdf=|usr=010}}
 
{{tp|p=32593196|t=2020. The Another Side of COVID-19 in Alzheimer's Disease Patients: Drug-Drug Interactions.|pdf=|usr=010}}
 
 
{{tp|p=32591771|t=2020. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.|pdf=|usr=010}}
 
 
{{tp|p=32586154|t=2020. Montelukast's ability to fight COVID-19 infection.|pdf=|usr=010}}
 
{{tp|p=32583729|t=2020. Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine.|pdf=|usr=010}}
 
{{tp|p=32579065|t=2020. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2.|pdf=|usr=010}}
 
 
{{tp|p=32579061|t=2020. Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL(pro).|pdf=|usr=010}}
 
 
{{tp|p=32573355|t=2020. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study.|pdf=|usr=010}}
 
 
{{tp|p=32571168|t=2020. Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target.|pdf=|usr=010}}
 
 
{{tp|p=32568618|t=2020. Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors.|pdf=|usr=010}}
 
{{tp|p=32568613|t=2020. Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors - an in silico docking and molecular dynamics simulation study.|pdf=|usr=010}}
 
{{tp|p=32568013|t=2020. Virtual screening and dynamics of potential inhibitors targeting RNA binding domain of nucleocapsid phosphoprotein from SARS-CoV-2.|pdf=|usr=010}}
 
{{tp|p=32568012|t=2020. Sars-cov-2 host entry and replication inhibitors from Indian ginseng: an in-silico approach.|pdf=|usr=010}}
 
{{tp|p=32567995|t=2020. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.|pdf=|usr=010}}
 
{{tp|p=32567989|t=2020. In silico identification of potential inhibitors from Cinnamon against main protease and spike glycoprotein of SARS CoV-2.|pdf=|usr=010}}
 
{{tp|p=32567979|t=2020. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.|pdf=|usr=010}}
 
{{tp|p=32567501|t=2020. Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics.|pdf=|usr=010}}
 
{{tp|p=32567487|t=2020. nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine.|pdf=|usr=010}}
 
{{tp|p=32568969|t=2020. Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019.|pdf=|usr=010}}
 
{{tp|p=32579707|t=2020. Clinical pharmacology considerations for developing small molecule treatments for COVID-19.|pdf=|usr=010}}
 
 
 
{{tp|p=32584243|t=2020. Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History.|pdf=|usr=010}}
 
{{tp|p=32591393|t=2020. A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.|pdf=|usr=010}}
 
 
{{tp|p=32559419|t=2020. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities.|pdf=|usr=010}}
 
 
{{tp|p=32574572|t=2020. Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients.|pdf=|usr=010}}
 
{{tp|p=32579258|t=2020. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.|pdf=|usr=010}}
 
{{tp|p=32578354|t=2020. Obesity and COVID-19: The mTOR pathway as a possible culprit.|pdf=|usr=010}}
 
 
{{tp|p=32588453|t=2020. Covid-19 and Thymoquinone: Connecting the Dots.|pdf=|usr=010}}
 
{{ttp|p=32552307|t=2020. A rationale for blocking thromboinflammation in COVID-19 with Btk inhibitors.|pdf=|usr=010}}
 
 
{{tp|p=32569363|t=2020. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study.|pdf=|usr=010}}
 
{{tp|p=32584474|t=2020. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.|pdf=|usr=010}}
 
{{tp|p=32568376|t=2020. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment.|pdf=|usr=010}}
 
{{tp|p=32556278|t=2020. Real-life experience of tocilizumab use in COVID-19 patients.|pdf=|usr=010}}
 
{{tp|p=32543892|t=2020. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.|pdf=|usr=010}}
 
{{tp|p=32590699|t=2020. ACTH 1-24 and other melanocortins for COVID-19 treatment.|pdf=|usr=010}}
 
 
{{tp|p=32573990|t=2020. Heart Transplant Recipient Patient with COVID-19 Treated with Tocilizumab.|pdf=|usr=010}}
 
{{tp|p=32584762|t=2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].|pdf=|usr=010}}
 
 
{{tp|p=32542847|t=2020. Clinical use of Convalescent Plasma in the COVID-19 pandemic; a transfusion-focussed gap analysis with recommendations for future research priorities.|pdf=|usr=010}}
 
 
 
{{tp|p=32547694|t=2020. Blocking Coronavirus 19 Infection via the SARS-CoV-2 Spike Protein: Initial Steps.|pdf=|usr=011}}
 
{{tp|p=32547693|t=2020. A Role for Metal-Based Drugs in Fighting COVID-19 Infection? The Case of Auranofin.|pdf=|usr=011}}
 
{{tp|p=32599103|t=2020. COVID-19 Fatalities, Latitude, Sunlight, and Vitamin D.|pdf=|usr=011}}
 
 
{{tp|p=32593520|t=2020. Tocilizumab en nino con leucemia linfoblastica aguda y sindrome de liberacion de citoquinas asociado a COVID-19.|pdf=|usr=011}}
 
{{tp|p=32566569|t=2020. Appealing for efficient, well organized clinical trials on COVID-19.|pdf=|usr=011}}
 
{{tp|p=32566564|t=2020. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis.|pdf=|usr=011}}
 
{{tp|p=32566562|t=2020. Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review.|pdf=|usr=011}}
 
{{tp|p=32566561|t=2020. Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis.|pdf=|usr=011}}
 
{{tp|p=32566896|t=2020. Perspectives on the development of neutralizing antibodies against SARS-CoV-2.|pdf=|usr=011}}
 
{{tp|p=32545171|t=2020. Antimicrobial Photodynamic Therapy in the Control of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32545518|t=2020. Nrf2 Activator PB125((R)) as a Potential Therapeutic Agent against COVID-19.|pdf=|usr=011}}
 
 
{{tp|p=32536457|t=2020. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy?|pdf=|usr=011}}
 
{{tp|p=32546446|t=2020. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?|pdf=|usr=011}}
 
 
{{tp|p=32594322|t=2020. Antiviral activity of berberine.|pdf=|usr=011}}
 
 
{{tp|p=32593613|t=2020. Testing of natural products in clinical trials targeting the SARS-CoV-2 (Covid-19) Viral Spike Protein-Angiotensin Converting Enzyme-2 (ACE2) interaction.|pdf=|usr=011}}
 
{{tp|p=32571182|t=2020. Molecular Targets in the Chemotherapy of Coronavirus Infection.|pdf=|usr=011}}
 
{{tp|p=32563698|t=2020. Repurposing old drugs as antiviral agents for coronaviruses.|pdf=|usr=011}}
 
 
 
{{tp|p=32599963|t=2020. Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.|pdf=|usr=011}}
 
{{tp|p=32536632|t=2020. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.|pdf=|usr=011}}
 
{{tp|p=32459144|t=2020. Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking.|pdf=|usr=011}}
 
{{tp|p=32420049|t=2020. Combating COVID-19 with Mesenchymal Stem Cell therapy.|pdf=|usr=011}}
 
{{tp|p=32493331|t=2020. An evidence mapping and analysis of registered COVID-19 clinical trials in China.|pdf=|usr=011}}
 
 
 
{{tp|p=32518212|t=2020. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.|pdf=|usr=011}}
 
{{tp|p=32532425|t=2020. Inclusion of pregnant women in clinical trials of COVID-19 therapies: what have we learned?|pdf=|usr=011}}
 
{{tp|p=32557557|t=2020. Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19?|pdf=|usr=011}}
 
 
{{tp|p=32571773|t=2020. Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.|pdf=|usr=011}}
 
{{tp|p=32407543|t=2020. Reflection on passive immunotherapy in those who need most: some novel strategic arguments for obtaining safer therapeutic plasma or autologous antibodies from recovered COVID-19 infected patients.|pdf=|usr=011}}
 
 
{{tp|p=32562276|t=2020. Statins: Could an old friend help the fight against COVID-19?|pdf=|usr=011}}
 
 
 
{{tp|p=32397275|t=2020. Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson's Disease.|pdf=|usr=011}}
 
{{tp|p=32603679|t=2020. Calcineurin inhibitors revisited: A new paradigm for COVID-19?|pdf=|usr=011}}
 
 
 
{{tp|p=32383125|t=2020. Prophylaxie post-exposition ou traitement preventif pour le syndrome respiratoire aigu severe du coronavirus 2 (SARS-CoV-2) : protocole d'etude pour une etude randomisee controlee pragmatique.|pdf=|usr=011}}
 
{{tp|p=32394335|t=2020. Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series.|pdf=|usr=011}}
 
{{tp|p=32385712|t=2020. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?|pdf=|usr=011}}
 
{{tp|p=32389579|t=2020. Irradiation pulmonaire a faible dose pour l'orage de cytokines du COVID-19 : pourquoi pas ?|pdf=|usr=011}}
 
{{tp|p=32599589|t=2020. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.|pdf=|usr=011}}
 
{{tp|p=32426243|t=2020. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report.|pdf=|usr=011}}
 
{{tp|p=32531248|t=2020. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.|pdf=|usr=011}}
 
{{tp|p=32547788|t=2020. Off-label therapy targeting pathogenic inflammation in COVID-19.|pdf=|usr=011}}
 
{{tp|p=32411313|t=2020. FAVORABLE ANAKINRA RESPONSES IN SEVERE COVID-19 PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS.|pdf=|usr=011}}
 
{{tp|p=32464097|t=2020. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.|pdf=|usr=011}}
 
{{tp|p=32413276|t=2020. Identification of Human Single-Domain Antibodies against SARS-CoV-2.|pdf=|usr=011}}
 
{{tp|p=32610043|t=2020. Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.|pdf=|usr=011}}
 
{{tp|p=32606347|t=2020. Distinct stem/progenitor cells proliferate to regenerate the trachea, intrapulmonary airways and alveoli in COVID-19 patients.|pdf=|usr=011}}
 
{{tp|p=32409956|t=2020. Possible application of H2S-producing compounds in therapy of coronavirus (COVID-19) infection and pneumonia.|pdf=|usr=011}}
 
{{tp|p=32606050|t=2020. COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach.|pdf=|usr=011}}
 
{{tp|p=32599278|t=2020. Imatinib for COVID-19: A case report.|pdf=|usr=011}}
 
{{tp|p=32603802|t=2020. Corticosteroid administration for viral pneumonia: COVID-19 and beyond.|pdf=|usr=011}}
 
 
{{tp|p=32610262|t=2020. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician's perspective.|pdf=|usr=011}}
 
{{tp|p=32601778|t=2020. Repurposed GI Drugs in the Treatment of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32593662|t=2020. Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders.|pdf=|usr=011}}
 
{{tp|p=32607779|t=2020. Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?|pdf=|usr=011}}
 
{{tp|p=32594204|t=2020. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?|pdf=|usr=011}}
 
 
{{tp|p=32603692|t=2020. Current pharmacological treatments for SARS-COV-2: A narrative review.|pdf=|usr=011}}
 
{{tp|p=32598953|t=2020. Drug treatment of coronavirus disease 2019 (COVID-19) in China.|pdf=|usr=011}}
 
{{tp|p=32598985|t=2020. Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections.|pdf=|usr=011}}
 
 
{{tp|p=32594820|t=2020. Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19.|pdf=|usr=011}}
 
{{tp|p=32606823|t=2020. Potential Role of Nrf2 Activators with Dual Antiviral and Anti-Inflammatory Properties in the Management of Viral Pneumonia.|pdf=|usr=011}}
 
 
{{tp|p=32610153|t=2020. COVID-19 trials in Italy: A call for simplicity, top standards and global pooling.|pdf=|usr=011}}
 
{{tp|p=32574504|t=2020. Metabolomics to Predict Antiviral Drug Efficacy in COVID-19.|pdf=|usr=011}}
 
{{tp|p=32597948|t=2020. Predicting Human Microbe-Drug Associations via Graph Convolutional Network with Conditional Random Field.|pdf=|usr=011}}
 
 
 
 
{{tp|p=32593183|t=2020. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.|pdf=|usr=011}}
 
{{tp|p=32593180|t=2020. Convalescent plasma for persisting Covid-19 following therapeutic lymphocyte depletion: a report of rapid recovery.|pdf=|usr=011}}
 
{{ttp|p=32584421|t=2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.|pdf=|usr=011}}
 
{{tp|p=32584416|t=2020. Amelioration of COVID-19 related cytokine storm syndrome: Parallels to chimeric antigen receptor-T cell cytokine release syndrome.|pdf=|usr=011}}
 
 
{{tp|p=32536693|t=2020. Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?|pdf=|usr=011}}
 
{{tp|p=32538775|t=2020. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-kappab pathways in non-pregnant and pregnant populations.|pdf=|usr=011}}
 
{{tp|p=32553536|t=2020. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes.|pdf=|usr=011}}
 
 
 
{{tp|p=32573419|t=2020. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.|pdf=|usr=011}}
 
{{tp|p=32597466|t=2020. Use of Baricitinib in Patients with Moderate and Severe COVID-19.|pdf=|usr=011}}
 
{{tp|p=32594142|t=2020. COVID-19 pharmacologic treatments for children: research priorities and approach to pediatric studies.|pdf=|usr=011}}
 
{{tp|p=32594120|t=2020. Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors.|pdf=|usr=011}}
 
{{tp|p=32588877|t=2020. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19.|pdf=|usr=011}}
 
{{tp|p=32585016|t=2020. THE RIGHT TIME FOR STEROIDS IN COVID-19.|pdf=|usr=011}}
 
{{tp|p=32575124|t=2020. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia.|pdf=|usr=011}}
 
{{tp|p=32604407|t=2020. Immune modulation in COVID-19: Strategic considerations for personalized therapeutic intervention.|pdf=|usr=011}}
 
{{tp|p=32602952|t=2020. Convalescent Plasma Therapy: Helpful Treatment of COVID-19 in a Kidney Transplant Recipient presenting with serve clinical manifestation and complex complications.|pdf=|usr=011}}
 
{{tp|p=32538717|t=2020. Structural Biology Aids the Research of New Anti-COVID-19 Drugs.|pdf=|usr=011}}
 
{{tp|p=32536564|t=2020. IL-15 immunotherapy is a viable strategy for COVID-19.|pdf=|usr=011}}
 
{{tp|p=32540737|t=2020. Use of pioglitazone in people with type 2 diabetes mellitus with coronavirus disease 2019 (COVID-19): Boon or bane?|pdf=|usr=011}}
 
 
{{tp|p=32538209|t=2020. Possible therapeutic agents for COVID-19: a comprehensive review.|pdf=|usr=011}}
 
{{tp|p=32603486|t=2020. Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.|pdf=|usr=011}}
 
 
{{tp|p=32603297|t=2020. Systematic Review and Meta-Analysis of the Efficacy of Nanoscale Materials Against Coronaviruses-Possible Potential Antiviral Agents for SARS-CoV-2.|pdf=|usr=011}}
 
{{tp|p=32603531|t=2020. Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial.|pdf=|usr=011}}
 
{{tp|p=32603576|t=2020. Vitamin D and Inflammation: Potential Implications for Severity of Covid-19.|pdf=|usr=011}}
 
 
{{tp|p=32518817|t=2020. Synthesis, Spectroscopic Characterizations of Novel Norcantharimides, Their ADME Properties and Docking Studies Against COVID-19 M(pr) degrees .|pdf=|usr=011}}
 
{{tp|p=32572383|t=2020. Evaluation of the Inhibitory Activities of COVID-19 of Melaleuca cajuputi Oil Using Docking Simulation.|pdf=|usr=011}}
 
 
{{tp|p=32548601|t=2020. Ventilation in the Dental Clinic: An Effective Measure to Control Droplets and Aerosols during the Coronavirus Pandemic and Beyond.|pdf=|usr=011}}
 
{{tp|p=32548600|t=2020. Preventive and Control Measures for the Coronavirus Pandemic in Clinical Dentistry.|pdf=|usr=011}}
 
{{tp|p=32242749|t=2020. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection?|pdf=|usr=011}}
 
{{tp|p=32513807|t=2020. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19?|pdf=|usr=011}}
 
{{tp|p=32533455|t=2020. Azithromycin for COVID-19: More Than Just an Antimicrobial?|pdf=|usr=011}}
 
 
{{tp|p=32492478|t=2020. Treating COVID-19 with colchicine in community healthcare setting.|pdf=|usr=011}}
 
{{tp|p=32544611|t=2020. Development of child immunity in the context of COVID-19 pandemic.|pdf=|usr=011}}
 
{{tp|p=32418917|t=2020. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!|pdf=|usr=011}}
 
{{tp|p=32417594|t=2020. Supplements for COVID-19: A modifiable environmental risk.|pdf=|usr=011}}
 
{{tp|p=32405269|t=2020. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.|pdf=|usr=011}}
 
{{tp|p=32409832|t=2020. SARS-CoV-2 pandemic : Time to revive the cyclophilin inhibitor alisporivir.|pdf=|usr=011}}
 
 
{{tp|p=32537133|t=2020. Potential Treatments for SARS-CoV-2 Infection.|pdf=|usr=011}}
 
 
{{tp|p=32454187|t=2020. Review of trials currently testing treatment and prevention of COVID-19.|pdf=|usr=011}}
 
 
 
{{tp|p=32407539|t=2020. Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?|pdf=|usr=011}}
 
 
{{tp|p=32311763|t=2020. Off-Label Therapies for COVID-19-Are We All In This Together?|pdf=|usr=011}}
 
{{tp|p=32451729|t=2020. Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.|pdf=|usr=011}}
 
{{tp|p=32394215|t=2020. Colchicine may not be effective in COVID-19 infection; it may even be harmful?|pdf=|usr=011}}
 
{{tp|p=32388748|t=2020. Reply to Rheumatologists' perspective on coronavirus disease 19: is heparin the dark horse for COVID-19?|pdf=|usr=011}}
 
 
{{tp|p=32575032|t=2020. Participation of more community hospitals in randomized trials of treatments for COVID-19 is needed.|pdf=|usr=011}}
 
{{tp|p=32493740|t=2020. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.|pdf=|usr=011}}
 
{{tp|p=32392494|t=2020. Sample sizes in COVID-19-related research.|pdf=|usr=011}}
 
{{tp|p=32485652|t=2020. Interaction of the prototypical alpha-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.|pdf=|usr=011}}
 
{{tp|p=32537526|t=2020. The critical role of futility analysis in the pursuit of effective treatments for COVID-19.|pdf=|usr=011}}
 
 
{{tp|p=32384906|t=2020. Use of triiodothyronine to treat critically ill COVID-19 patients: a new clinical trial.|pdf=|usr=011}}
 
{{tp|p=32430057|t=2020. Adjuvant corticosteroid therapy for critically ill patients with COVID-19.|pdf=|usr=011}}
 
{{tp|p=32414417|t=2020. Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure.|pdf=|usr=011}}
 
{{tp|p=32513242|t=2020. Blocking mineralocorticoid receptor with spironolactone may have a wide range of therapeutic actions in severe COVID-19 disease.|pdf=|usr=011}}
 
{{tp|p=32513225|t=2020. Neutrophil Elastase Inhibitors: A potential prophylactic treatment option for SARS-CoV-2-induced respiratory complications?|pdf=|usr=011}}
 
{{tp|p=32487260|t=2020. Precision medicine for COVID-19: a call for better clinical trials.|pdf=|usr=011}}
 
{{tp|p=32487139|t=2020. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?|pdf=|usr=011}}
 
{{tp|p=32532353|t=2020. Interferon beta-1a for COVID-19: critical importance of the administration route.|pdf=|usr=011}}
 
{{tp|p=32527304|t=2020. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.|pdf=|usr=011}}
 
{{tp|p=32544802|t=2020. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature.|pdf=|usr=011}}
 
{{tp|p=32460133|t=2020. Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments.|pdf=|usr=011}}
 
{{tp|p=32494546|t=2020. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.|pdf=|usr=011}}
 
 
{{tp|p=32596078|t=2020. Emerging Pharmaceutical Treatments of Novel COVID-19: A Review.|pdf=|usr=011}}
 
{{tp|p=32577324|t=2020. COVID-19: A Review of Emerging Preventative Vaccines and Treatment Strategies.|pdf=|usr=011}}
 
{{tp|p=32550078|t=2020. Heated Air Delivery by Micro-Sauna: An Experimental Treatment Prototype Concept for Coronavirus Disease 2019.|pdf=|usr=011}}
 
{{tp|p=32540367|t=2020. A review of potential treatments to date in COVID-19 patients according to the stage of the disease.|pdf=|usr=011}}
 
{{tp|p=32563554|t=2020. Should we unstress SARS-CoV-2 infected cells?|pdf=|usr=011}}
 
{{tp|p=32565132|t=2020. Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies.|pdf=|usr=011}}
 
 
{{tp|p=32563941|t=2020. Letter in response to the article: Vitamin D concentrations and COVID-19 infection in UK biobank (Hastie et al.).|pdf=|usr=011}}
 
{{tp|p=32593491|t=2020. Molecular pharmacology of ciclesonide against SARS-CoV-2.|pdf=|usr=011}}
 
 
{{tp|p=32607505|t=2020. COVID-19 Clinical Research.|pdf=|usr=011}}
 
{{tp|p=32605278|t=2020. Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19.|pdf=|usr=011}}
 
{{tp|p=32605780|t=2020. Role of vitamin D in preventing of COVID-19 infection, progression and severity.|pdf=|usr=011}}
 
 
{{tp|p=32605149|t=2020. Bioactive Indolyl Diketopiperazines from the Marine Derived Endophytic Aspergillus versicolor DY180635.|pdf=|usr=011}}
 
{{tp|p=32593831|t=2020. Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19.|pdf=|usr=011}}
 
{{tp|p=32604775|t=2020. A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era.|pdf=|usr=011}}
 
{{tp|p=32593740|t=2020. Irisin modulates genes associated with severe coronavirus disease (COVID-19) outcome in human subcutaneous adipocytes.|pdf=|usr=011}}
 
{{tp|p=32602074|t=2020. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32603575|t=2020. Vitamin D Deficiency and ARDS after SARS-CoV-2 Infection.|pdf=|usr=011}}
 
{{tp|p=32603574|t=2020. Vitamin D and Covid-19: A Note of Caution.|pdf=|usr=011}}
 
{{tp|p=32603573|t=2020. Covid-19, Cocooning and Vitamin D Intake Requirements.|pdf=|usr=011}}
 
 
{{tp|p=32551464|t=2020. Dexamethasone for COVID-19? Not so fast.|pdf=|usr=011}}
 
{{tp|p=32597315|t=2020. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.|pdf=|usr=011}}
 
{{tp|p=32608329|t=2020. In silico analysis and identification of promising hits against 2019 novel coronavirus 3C-like main protease enzyme.|pdf=|usr=011}}
 
{{tp|p=32520770|t=2020. Overview of Coronavirus Disease 2019 (COVID-19): Treatment Updates and Advances.|pdf=|usr=011}}
 
{{tp|p=32530870|t=2020. Rapid Review: Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 Infections.|pdf=|usr=011}}
 
{{tp|p=32570043|t=2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care.|pdf=|usr=011}}
 
{{tp|p=32574020|t=2020. Biologics and Small Molecules in the Treatment of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32559285|t=2020. Interferon-beta 1a inhibits SARS-CoV-2 in vitro when administered after virus infection.|pdf=|usr=011}}
 
{{tp|p=32603493|t=2020. Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study.|pdf=|usr=011}}
 
{{tp|p=32583447|t=2020. SARS-COV-2 and biomimetics: What saves the planet will save our health.|pdf=|usr=011}}
 
{{tp|p=32579254|t=2020. SARS-CoV-2 and SARS-CoV: Virtual Screening of Potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12).|pdf=|usr=011}}
 
{{tp|p=32568411|t=2020. Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm.|pdf=|usr=011}}
 
{{tp|p=32574379|t=2020. A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer"on https://doi.org/10.1111/jnc.15021.|pdf=|usr=011}}
 
{{ttp|p=32597503|t=2020. Melatonin Restores Neutrophil Functions and Prevents Apoptosis amid Dysfunctional Glutathione Redox System.|pdf=|usr=011}}
 
{{tp|p=32543164|t=2020. The comparison of the effectiveness of lincocin(R) and azitro(R) in the treatment of covid-19-associated pneumonia: A prospective study.|pdf=|usr=011}}
 
{{tp|p=32608097|t=2020. Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses.|pdf=|usr=011}}
 
 
{{tp|p=32568282|t=2020. Emerging pharmacotherapy for COVID-19.|pdf=|usr=011}}
 
 
{{tp|p=32515802|t=2020. Existing Drugs Might Treat COVID-19.|pdf=|usr=011}}
 
{{tp|p=32539093|t=2020. Monoclonal Antibodies for Prevention and Treatment of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32544372|t=2020. Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold.|pdf=|usr=011}}
 
 
{{tp|p=32541129|t=2020. Intermittent high dosage oxygen treats COVID-19 infection: the Chinese studies.|pdf=|usr=011}}
 
{{tp|p=32541128|t=2020. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure.|pdf=|usr=011}}
 
{{tp|p=32594562|t=2020. Clinical trials for the prevention and treatment of COVID-19: current state of play.|pdf=|usr=011}}
 
 
{{tp|p=32447665|t=2020. Mit IL-6-Inhibitor gegen COVID-19 : Corona-Pandemie.|pdf=|usr=011}}
 
{{tp|p=32342366|t=2020. Autophagie - ein Ansatzpunkt fur ein Medikament gegen COVID-19? : Kampf gegen das Coronavirus.|pdf=|usr=011}}
 
 
 
{{tp|p=32581514|t=2020. Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov.|pdf=|usr=011}}
 
{{tp|p=32524646|t=2020. Lithium as a candidate treatment for COVID-19: Promises and pitfalls.|pdf=|usr=011}}
 
 
{{tp|p=32425222|t=2020. Repurposing chlorpromazine to treat COVID-19: The reCoVery study.|pdf=|usr=011}}
 
 
{{tp|p=32482571|t=2020. Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.|pdf=|usr=011}}
 
{{tp|p=32544799|t=2020. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.|pdf=|usr=011}}
 
 
{{tp|p=32563814|t=2020. Fight against novel coronavirus: A perspective of medicinal chemists.|pdf=|usr=011}}
 
{{tp|p=32563813|t=2020. Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase.|pdf=|usr=011}}
 
{{tp|p=32525005|t=2020. Effective block by pirfenidone, an antifibrotic pyridone compound (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated cation current: An additional but distinctive target.|pdf=|usr=011}}
 
{{tp|p=32563675|t=2020. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.|pdf=|usr=011}}
 
{{tp|p=32536989|t=2020. IgY - turning the page toward passive immunization in COVID-19 infection (Review).|pdf=|usr=011}}
 
{{tp|p=32536988|t=2020. [Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver.|pdf=|usr=011}}
 
{{tp|p=32537481|t=2020. EML webinar overview: Simulation-assisted discovery of membrane targeting nanomedicine.|pdf=|usr=011}}
 
{{tp|p=32399192|t=2020. Recent advances in influenza vaccines.|pdf=|usr=011}}
 
{{tp|p=32574317|t=2020. Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections.|pdf=|usr=011}}
 
{{tp|p=32596244|t=2020. The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and Its Potential Use in the Associated Severe Pneumonia.|pdf=|usr=011}}
 
{{tp|p=32595653|t=2020. Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.|pdf=|usr=011}}
 
{{tp|p=32582221|t=2020. Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline.|pdf=|usr=011}}
 
{{tp|p=32574274|t=2020. Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing?|pdf=|usr=011}}
 
{{tp|p=32574273|t=2020. Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?|pdf=|usr=011}}
 
{{tp|p=32574268|t=2020. Fighting the Host Reaction to SARS-COv-2 in Critically Ill Patients: The Possible Contribution of Off-Label Drugs.|pdf=|usr=011}}
 
{{tp|p=32574267|t=2020. COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.|pdf=|usr=011}}
 
{{tp|p=32574263|t=2020. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.|pdf=|usr=011}}
 
{{tp|p=32574262|t=2020. Interferon-alpha2b Treatment for COVID-19.|pdf=|usr=011}}
 
{{tp|p=32574259|t=2020. Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32574258|t=2020. Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?|pdf=|usr=011}}
 
{{tp|p=32582742|t=2020. The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection.|pdf=|usr=011}}
 
 
{{tp|p=32574339|t=2020. Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia.|pdf=|usr=011}}
 
{{tp|p=32574332|t=2020. Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.|pdf=|usr=011}}
 
{{tp|p=32574331|t=2020. May Polyphenols Have a Role Against Coronavirus Infection? An Overview of in vitro Evidence.|pdf=|usr=011}}
 
{{tp|p=32574327|t=2020. Therapeutic Algorithm for Use of Melatonin in Patients With COVID-19.|pdf=|usr=011}}
 
{{tp|p=32574320|t=2020. Doxycycline: From Ocular Rosacea to COVID-19 Anosmia. New Insight Into the Coronavirus Outbreak.|pdf=|usr=011}}
 
 
{{tp|p=32582138|t=2020. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection.|pdf=|usr=011}}
 
{{tp|p=32582137|t=2020. Biosurfactants: A Covid-19 Perspective.|pdf=|usr=011}}
 
{{tp|p=32582134|t=2020. Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections.|pdf=|usr=011}}
 
{{tp|p=32582766|t=2020. Does Early Childhood Vaccination Protect Against COVID-19?|pdf=|usr=011}}
 
{{tp|p=32581810|t=2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.|pdf=|usr=011}}
 
{{tp|p=32581809|t=2020. Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32574238|t=2020. An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?|pdf=|usr=011}}
 
 
 
 
 
{{tp|p=32574290|t=2020. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic.|pdf=|usr=011}}
 
{{tp|p=32574289|t=2020. Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?|pdf=|usr=011}}
 
{{tp|p=32547908|t=2020. Ultraviolet irradiation doses for coronavirus inactivation - review and analysis of coronavirus photoinactivation studies.|pdf=|usr=011}}
 
{{tp|p=32566483|t=2020. Doxycycline as a potential partner of COVID-19 therapies.|pdf=|usr=011}}
 
 
{{tp|p=32546458|t=2020. Covid-19 chemoprophylaxis: Ethics of prevention based on anecdotal evidence.|pdf=|usr=011}}
 
{{tp|p=32540428|t=2020. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.|pdf=|usr=011}}
 
{{tp|p=32537482|t=2020. Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach.|pdf=|usr=011}}
 
{{tp|p=32544867|t=2020. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial.|pdf=|usr=011}}
 
{{tp|p=32544570|t=2020. Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon beta-1b.|pdf=|usr=011}}
 
{{tp|p=32534513|t=2020. COVID-19 Pandemic Hemoperfusion Therapy Versus Plasma Exchange Therapy in Intensive Care.|pdf=|usr=011}}
 
{{tp|p=32534509|t=2020. Management of COVID-19 Virus Infection by Convalescent Plasma.|pdf=|usr=011}}
 
{{tp|p=32534505|t=2020. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung.|pdf=|usr=011}}
 
{{tp|p=32558435|t=2020. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond.|pdf=|usr=011}}
 
{{tp|p=32565398|t=2020. Effects of Micronutrients or Conditional Amino Acids on COVID-19-Related Outcomes: An Evidence Analysis Center Scoping Review.|pdf=|usr=011}}
 
{{tp|p=32587093|t=2020. Inhibition of SARS-CoV-2 by type I and type III interferons.|pdf=|usr=011}}
 
{{tp|p=32552595|t=2020. Natural compounds from Clerodendrum spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation.|pdf=|usr=011}}
 
{{tp|p=32552534|t=2020. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.|pdf=|usr=011}}
 
{{tp|p=32552462|t=2020. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study.|pdf=|usr=011}}
 
{{tp|p=32552361|t=2020. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro).|pdf=|usr=011}}
 
{{tp|p=32544024|t=2020. An in silico approach for identification of novel inhibitors as potential therapeutics targeting COVID-19 main protease.|pdf=|usr=011}}
 
{{tp|p=32543978|t=2020. Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV-2 in comparison to known antiviral compounds in drug trials.|pdf=|usr=011}}
 
{{tp|p=32538276|t=2020. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies.|pdf=|usr=011}}
 
{{tp|p=32554907|t=2020. Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials.|pdf=|usr=011}}
 
{{tp|p=32603772|t=2020. Targeting inflammation and cytokine storm in COVID-19.|pdf=|usr=011}}
 
 
{{ttp|p=32600125|t=2020. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection.|pdf=|usr=011}}
 
{{tp|p=32594863|t=2020. The potential role of nanomedicine on COVID-19 therapeutics.|pdf=|usr=011}}
 
{{tp|p=32593519|t=2020. Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.|pdf=|usr=011}}
 
 
{{tp|p=32605306|t=2020. Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.|pdf=|usr=011}}
 
{{tp|p=32546811|t=2020. Coronavirus breakthrough: dexamethasone is first drug shown to save lives.|pdf=|usr=011}}
 
{{tp|p=32071447|t=2020. More than 80 clinical trials launch to test coronavirus treatments.|pdf=|usr=011}}
 
{{tp|p=32214238|t=2020. How blood from coronavirus survivors might save lives.|pdf=|usr=011}}
 
{{tp|p=32597513|t=2020. New intrigant possibility for prevention of coronavirus pneumonitis: natural purified polyphenols.|pdf=|usr=011}}
 
{{tp|p=32541085|t=2020. Citokinellenes terapia az uj tipusu koronavirus okozta megbetegedes (COVID-19) kezeleseben - tocilizumab elsokent valo alkalmazasa egy hazai infektologiai osztalyon.|pdf=|usr=011}}
 
{{tp|p=32564002|t=2020. Az elso ket sikeres, convalescens friss fagyasztott plazmaval torteno terapia hazai alkalmazasa intenziv osztalyon kezelt, kritikus allapotu, COVID-19-fertozesben szenvedo betegekben: (A COVID-19-pandemia orvosszakmai kerdesei)|pdf=|usr=011}}
 
{{tp|p=32579049|t=2020. Photobiomodulation: Shining Light on COVID-19.|pdf=|usr=011}}
 
{{tp|p=32579493|t=2020. Response to: Can Transdermal Photobiomodulation Help Us at the Time of COVID-19?|pdf=|usr=011}}
 
{{tp|p=32579491|t=2020. Author's Response to Ferreira: Can Transdermal Photobiomodulation Help Us at the Time of COVID-19? An Update.|pdf=|usr=011}}
 
 
{{tp|p=32584322|t=2020. INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY.|pdf=|usr=011}}
 
 
 
 
{{tp|p=32604223|t=2020. Therapeutic Potential of B-1a Cells in COVID-19.|pdf=|usr=011}}
 
{{tp|p=32553502|t=2020. Ultrafast response of the French Society of Pharmacology and Therapeutics to the COVID-19 pandemic.|pdf=|usr=011}}
 
{{tp|p=32561113|t=2020. Current treatment approaches for COVID-19 and the clinical value of transfusion-related technologies.|pdf=|usr=011}}
 
{{tp|p=32574447|t=2020. HBO2 for COVID-19: Clinical trials at clinicaltrials.gov.|pdf=|usr=011}}
 
{{tp|p=32574446|t=2020. UHMS Position Statement: Hyperbaric Oxygen (HBO2) for COVID-19 Patients.|pdf=|usr=011}}
 
{{tp|p=32574433|t=2020. Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports.|pdf=|usr=011}}
 
{{tp|p=32574432|t=2020. Hyperbaric oxygen as a treatment for COVID-19 infection?|pdf=|usr=011}}
 
{{tp|p=32567972|t=2020. Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway.|pdf=|usr=011}}
 
 
 
{{tp|p=32530282|t=2020. Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease.|pdf=|usr=011}}
 
{{tp|p=32539372|t=2020. Fragment Molecular Orbital Based Interaction Analyses on COVID-19 Main Protease - Inhibitor N3 Complex (PDB ID: 6LU7).|pdf=|usr=011}}
 
{{tp|p=32551639|t=2020. Discovery of New Hydroxyethylamine Analogs against 3CL(pro) Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies.|pdf=|usr=011}}
 
 
{{tp|p=32560227|t=2020. Vaccines and Therapies in Development for SARS-CoV-2 Infections.|pdf=|usr=011}}
 
 
{{tp|p=32524645|t=2020. Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring.|pdf=|usr=011}}
 
{{tp|p=32535939|t=2020. Critical Need for Implementation of Clinical Pharmacology Principles in Developing Drugs for the Treatment or Prevention of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32557271|t=2020. Possible role of vitamin D in Covid-19 infection in pediatric population.|pdf=|usr=011}}
 
{{tp|p=32551855|t=2020. Effects of Gene-Eden-VIR and Novirin on SARS-CoV: Implications for COVID-19.|pdf=|usr=011}}
 
{{tp|p=32560382|t=2020. "Monoclonal-Type" Plastic Antibodies for COVID-19 Treatment: What Is the Idea?|pdf=|usr=011}}
 
{{tp|p=32592703|t=2020. Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia.|pdf=|usr=011}}
 
{{tp|p=32579985|t=2020. Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients: Etoposide for severe COVID-19 patients.|pdf=|usr=011}}
 
 
{{tp|p=32515499|t=2020. Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6.|pdf=|usr=011}}
 
 
{{tp|p=32530507|t=2020. Can steroids reverse the severe COVID-19 induced "cytokine storm"?|pdf=|usr=011}}
 
 
{{tp|p=32519764|t=2020. Could melatonin be used in COVID-19 patients with laryngopharyngeal reflux disease?|pdf=|usr=011}}
 
 
{{tp|p=32454982|t=2020. Amid COVID-19: the importance of developing an positive adverse drug reaction (ADR) and medical device incident (MDI) reporting culture for Global Health and public safety.|pdf=|usr=011}}
 
{{tp|p=32542782|t=2020. SARS-CoV-2 Viral Inactivation Using Low Dose Povidone-Iodine Oral Rinse-Immediate Application for the Prosthodontic Practice.|pdf=|usr=011}}
 
{{tp|p=32582350|t=2020. Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property.|pdf=|usr=011}}
 
{{tp|p=32600410|t=2020. Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.|pdf=|usr=011}}
 
{{tp|p=32579195|t=2020. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial.|pdf=|usr=011}}
 
{{tp|p=32579190|t=2020. Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19)-An Old Drug With New Life?|pdf=|usr=011}}
 
 
{{tp|p=32539990|t=2020. A minimal common outcome measure set for COVID-19 clinical research.|pdf=|usr=011}}
 
{{tp|p=32402512|t=2020. A Case of Coronavirus Disease 2019 Treated With Ciclesonide.|pdf=|usr=011}}
 
{{tp|p=32577056|t=2020. The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role?|pdf=|usr=011}}
 
{{tp|p=32537610|t=2020. Inhibition of metalloproteinases in therapy for severe lung injury due to COVID-19.|pdf=|usr=011}}
 
{{tp|p=32563969|t=2020. Can hyperimmune anti-CMV globulin substitute for convalescent plasma for treatment of COVID-19?|pdf=|usr=011}}
 
 
{{tp|p=32540604|t=2020. Iodine, a preventive and curative agent in the COVID-19 pandemic?|pdf=|usr=011}}
 
{{tp|p=32562911|t=2020. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.|pdf=|usr=011}}
 
{{tp|p=32554324|t=2020. Noradrenergic and serotonergic drugs may have opposing effects on COVID-19 cytokine storm and associated psychological effects.|pdf=|usr=011}}
 
{{tp|p=32540603|t=2020. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19.|pdf=|usr=011}}
 
{{tp|p=32563970|t=2020. Deceiving SARS-CoV-2 molecular-tropism clues - A combinational contemporary strategy.|pdf=|usr=011}}
 
{{ttp|p=32590321|t=2020. Endothelial progenitor cells and mesenchymal stem cells to overcome vascular deterioration and cytokine storm in critical patients with COVID-19.|pdf=|usr=011}}
 
{{tp|p=32554149|t=2020. Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy.|pdf=|usr=011}}
 
 
{{tp|p=32538585|t=2020. Reply to: What we are talking about when we talk of steroid in COVID-19?|pdf=|usr=011}}
 
{{tp|p=32538591|t=2020. Convalescent plasma and covid-19 treatment.|pdf=|usr=011}}
 
{{tp|p=32447695|t=2020. Therapien gegen COVID-19 - ein Update : SARS-CoV-2-Pandemie.|pdf=|usr=011}}
 
{{tp|p=32405836|t=2020. Wie ernahre ich mich am besten in Zeiten der Corona-Pandemie? : COVID-19 und Ernahrungsmedizin.|pdf=|usr=011}}
 
 
{{tp|p=32545268|t=2020. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.|pdf=|usr=011}}
 
{{tp|p=32561155|t=2020. Inmunoglobulinas por via intravenosa: una alternativa terapeutica a tener en cuenta en el paciente trasplantado renal con COVID-19.|pdf=|usr=011}}
 
 
 
{{tp|p=32550240|t=2020. Azithromycin Should Not Be Used to Treat COVID-19.|pdf=|usr=011}}
 
{{tp|p=32582329|t=2020. How Nutrition can help to fight against COVID-19 Pandemic.|pdf=|usr=011}}
 
{{tp|p=32582320|t=2020. Beyond transmission: Dire need for integration of nutrition interventions in COVID-19 pandemic-response strategies in Developing Countries like Pakistan.|pdf=|usr=011}}
 
{{tp|p=32582873|t=2020. Evaluation of Ultraviolet-C Light for Rapid Decontamination of Airport Security Bins in the Era of SARS-CoV-2.|pdf=|usr=011}}
 
{{tp|p=32566414|t=2020. Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach.|pdf=|usr=011}}
 
{{tp|p=32578336|t=2020. Buying time: Drug repurposing to treat the host in COVID-19H.|pdf=|usr=011}}
 
{{tp|p=32380821|t=2020. Therapeutic plasma exchange as a rescue therapy in patients with coronavirus disease 2019: a case series.|pdf=|usr=011}}
 
{{tp|p=32383835|t=2020. Acute respiratory distress syndrome and steroids in the shadow of coronavirus disease 2019.|pdf=|usr=011}}
 
{{tp|p=32540682|t=2020. Psychotropics drugs with cationic amphiphilic properties may afford some protection against SARS-CoV-2: A mechanistic hypothesis.|pdf=|usr=011}}
 
{{tp|p=32590235|t=2020. TB infection and BCG vaccination: are we protected from COVID-19?|pdf=|usr=011}}
 
  
 +
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
 +
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
 +
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
 +
Paper is (not yet in PubMed) :
  
{{tp|p=32583654|t=2020. Baricitinib en el tratamiento de infeccion por SARS-CoV-2.|pdf=|usr=011}}
+
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
{{tp|p=32595974|t=2020. The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure.|pdf=|usr=011}}
+
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
{{tp|p=32548259|t=2020. Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents.|pdf=|usr=011}}
+
based on e.g.
{{tp|p=32601278|t=2020. Numerical evaluation of spray position for improved nasal drug delivery.|pdf=|usr=011}}
+
{{tp|p=32581288|t=2020. Far-UVC light (222 nm) efficiently and safely inactivates airborne human coronaviruses.|pdf=|usr=011}}
+
{{tp|p=32576928|t=2020. DREAM-in-CDM Approach and Identification of a New Generation of Anti-inflammatory Drugs Targeting mPGES-1.|pdf=|usr=011}}
+
{{tp|p=32571838|t=2020. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.|pdf=|usr=011}}
+
{{tp|p=32540904|t=2020. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies.|pdf=|usr=011}}
+
{{tp|p=32540903|t=2020. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.|pdf=|usr=011}}
+
{{tp|p=32540902|t=2020. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.|pdf=|usr=011}}
+
{{tp|p=32540901|t=2020. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.|pdf=|usr=011}}
+
{{tp|p=32540900|t=2020. Broad neutralization of SARS-related viruses by human monoclonal antibodies.|pdf=|usr=011}}
+
{{tp|p=32570174|t=2020. SARS-CoV-2 infection and stem cells: Interaction and intervention.|pdf=|usr=011}}
+
{{tp|p=32592163|t=2020. 'Primed' Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients.|pdf=|usr=011}}
+
{{tp|p=32564256|t=2020. Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.|pdf=|usr=011}}
+
{{tp|p=32577236|t=2020. Preventing SARS-CoV-2 infection by blocking a tissue serine protease.|pdf=|usr=011}}
+
{{tp|p=32539647|t=2020. Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients.|pdf=|usr=011}}
+
{{tp|p=32583289|t=2020. Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic.|pdf=|usr=011}}
+
{{tp|p=32557317|t=2020. New FDA Guidance on General Clinical Trial Conduct in the Era of COVID-19.|pdf=|usr=011}}
+
  
{{tp|p=32540345|t=2020. Anti-SARS-CoV-2 hyperimmune plasma workflow.|pdf=|usr=011}}
+
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
{{tp|p=32563550|t=2020. Plasma from donors convalescent from SARS-CoV-2 infection-A matter of priorities.|pdf=|usr=011}}
+
{{tp|p=32359090|t=2020. Convalescent plasma: possible therapy for novel coronavirus disease 2019.|pdf=|usr=011}}
+
{{tp|p=32563584|t=2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report.|pdf=|usr=011}}
+
  
{{tp|p=32580895|t=2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.|pdf=|usr=011}}
+
=======================================================================================
{{ttp|p=32551457|t=2020. Possible Old Drugs for Repositioning in COVID-19 Treatment: Combating Cytokine Storms from Haloperidol to Anti-interleukin Agents.|pdf=|usr=011}}
+
{{tp|p=32551456|t=2020. Use of Spironolactone in SARS-CoV-2 ARDS Patients.|pdf=|usr=011}}
+
{{tp|p=32595362|t=2020. Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection.|pdf=|usr=011}}
+
{{tp|p=32595360|t=2020. Interaction of certain monoterpenoid hydrocarbons with the receptor binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties.|pdf=|usr=011}}
+
{{tp|p=32595359|t=2020. Potentials of plant-based substance to inhabit and probable cure for the COVID-19.|pdf=|usr=011}}
+
  
{{tp|p=32595357|t=2020. SARS-CoV-2 neutralizing antibody development strategies.|pdf=|usr=011}}
+
COVID19 is now a CURABLE disease !!!
{{tp|p=32595355|t=2020. Virtual drug repurposing study against SARS-CoV-2 TMPRSS2 target.|pdf=|usr=011}}
+
{{tp|p=32585913|t=2020. SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries.|pdf=|usr=011}}
+
{{tp|p=32575350|t=2020. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.|pdf=|usr=011}}
+
  
{{tp|p=32560646|t=2020. Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.|pdf=|usr=011}}
+
=======================================================================================
{{tp|p=32592817|t=2020. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.|pdf=|usr=011}}
+
{{tp|p=32569708|t=2020. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.|pdf=|usr=011}}
+
{{tp|p=32565126|t=2020. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.|pdf=|usr=011}}
+
{{tp|p=32545799|t=2020. Potential Antiviral Options against SARS-CoV-2 Infection.|pdf=|usr=011}}
+
{{tp|p=32573126|t=2020. Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?|pdf=|usr=011}}
+

Aktuelle Version vom 21. September 2021, 06:15 Uhr

homepage
hottest actual papers
 P further streaming-in related content is here
 CHERRYPICKING STUDIES IS NOT SCIENCE
Reviews on covid drug development


PHA related options:


A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis